12 analysts have shared their evaluations of Hologic HOLX during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 5 | 5 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 3 | 2 | 0 | 0 |
| 3M Ago | 1 | 2 | 2 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $88.92, a high estimate of $95.00, and a low estimate of $82.00. This current average reflects an increase of 0.01% from the previous average price target of $88.91.
Deciphering Analyst Ratings: An In-Depth Analysis
A clear picture of Hologic's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tycho Peterson | Jefferies | Announces | Hold | $85.00 | - |
| Andrew Cooper | Raymond James | Raises | Outperform | $95.00 | $93.00 |
| Anthony Petrone | Mizuho | Lowers | Outperform | $87.00 | $90.00 |
| Elizabeth Garcia | UBS | Raises | Neutral | $90.00 | $84.00 |
| Conor McNamara | RBC Capital | Raises | Sector Perform | $89.00 | $86.00 |
| Casey Woodring | JP Morgan | Raises | Overweight | $94.00 | $92.00 |
| Mike Matson | Needham | Maintains | Buy | $90.00 | $90.00 |
| Puneet Souda | Leerink Partners | Lowers | Outperform | $90.00 | $95.00 |
| Anthony Petrone | Mizuho | Raises | Outperform | $90.00 | $85.00 |
| Vijay Kumar | Evercore ISI Group | Raises | In-Line | $82.00 | $78.00 |
| Patrick Donnelly | Citigroup | Lowers | Neutral | $85.00 | $95.00 |
| Mike Matson | Needham | Maintains | Buy | $90.00 | $90.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Hologic. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hologic compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Hologic's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Hologic analyst ratings.
Unveiling the Story Behind Hologic
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Financial Insights: Hologic
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Hologic's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 4.52%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Hologic's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 18.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Hologic's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.54%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Hologic's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.98%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.52.
Understanding the Relevance of Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
